請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62898完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林育誼 | |
| dc.contributor.author | Wei-Hsiao Li | en |
| dc.contributor.author | 李偉孝 | zh_TW |
| dc.date.accessioned | 2021-06-16T16:14:09Z | - |
| dc.date.available | 2014-08-31 | |
| dc.date.copyright | 2013-03-04 | |
| dc.date.issued | 2013 | |
| dc.date.submitted | 2013-02-07 | |
| dc.identifier.citation | Blaschuk, O., Burdzy, K., and Fritz, I. B. (1983). Purification and Characterization of a Cell-Aggregating Factor (Clusterin), the Major Glycoprotein in Ram Rete Testis Fluid. J Biol Chem 258, 7714-7720.
Bruix, J., and Sherman, M. (2011). Management of Hepatocellular Carcinoma: An Update. Hepatology 53, 1020-1022. Cheng, J. C. H., Chou, C. H., Kuo, M. L., and Hsieh, C. Y. (2006). Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappa B signal transduction pathway. Oncogene 25, 7009-7018. Chi, K. N., Hotte, S. J., Yu, E. Y., Tu, D. S., Eigl, B. J., Tannock, I., Saad, F., North, S., Powers, J., Gleave, M. E., and Eisenhauer, E. A. (2010). Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology 28, 4247-4254. Cliby, W. A., Roberts, C. J., Cimprich, K. A., Stringer, C. M., Lamb, J. R., Schreiber, S. L., and Friend, S. H. (1998). Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. The EMBO journal 17, 159-169. Criswell, T., Beman, M., Araki, S., Leskov, K., Cataldo, E., Mayo, L. D., and Boothman, D. A. (2005). Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem 280, 14212-14221. El-Serag, H. B. (2011). Current Concepts Hepatocellular Carcinoma. New Engl J Med 365, 1118-1127. Forner, A., Llovet, J. M., and Bruix, J. (2012). Hepatocellular carcinoma. Lancet 379, 1245-1255. Goetz, E. M., Shankar, B., Zou, Y., Morales, J. C., Luo, X., Araki, S., Bachoo, R., Mayo, L. D., and Boothman, D. A. (2011). ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. Oncogene 30, 3745-3754. Hara, I., Miyake, H., Gleave, M. E., and Kamidono, S. (2001). Introduction of Clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res 92, 1220-1224. Hawkins, M. A., and Dawson, L. A. (2006). Radiation therapy for hepatocellular carcinoma - From palliation to cure. Cancer 106, 1653-1663. Kang, Y. K., Hong, S. W., Lee, H. S., and Kim, W. H. (2004). Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol 35, 1340-1346. Lau, S. H., Sham, J. S. T., Xie, D., Tzang, C. H., Tang, D., Ma, N., Hu, L., Wang, Y., Wen, J. M., Xiao, G., et al. (2006). Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25, 1242-1250. Leskov, K. S., Klokov, D. Y., Li, J., Kinsella, T. J., and Boothman, D. A. (2003). Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278, 11590-11600. Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008a). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer I 100, 698-711. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A., et al. (2008b). Sorafenib in advanced hepatocellular carcinoma. New Engl J Med 359, 378-390. Mohr, S., Bakal, C., and Perrimon, N. (2010). Genomic Screening with RNAi: Results and Challenges. Annu Rev Biochem 79, 37-64. Mullenders, J., and Bernards, R. (2009). Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 28, 4409-4420. Pucci, S., Bonanno, E., Pichiorri, F., Angeloni, C., and Spagnoli, L. G. (2004). Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23, 2298-2304. Redondo, M., Villar, E., Torres-Munoz, J., Tellez, T., Morell, M., and Petito, C. K. (2000). Overexpression of clusterin in human breast carcinoma. Am J Pathol 157, 393-399. Sanyal, A. J., Yoon, S. K., and Lencioni, R. (2010). The Etiology of Hepatocellular Carcinoma and Consequences for Treatment. Oncologist 15, 14-22. Shin, K. H., Ahn, J. H., Kang, M. K., Lim, P. K., Yip, F. K., Baluda, M. A., and Park, N. H. (2006). HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and -independent pathways. International Journal of Oncology 28, 209-215. Thomas, M. (2009). Molecular targeted therapy for hepatocellular carcinoma. Journal of Gastroenterology 44, 136-141. Trougakos, I. P., So, A., Jansen, B., Gleave, M. E., and Gonos, E. S. (2004). Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64, 1834-1842. Yang, C. R., Yeh, S. Y., Leskov, K., Odegaard, E., Hsu, H. L., Chang, C. S., Kinsella, T. J., Chen, D. J., and Boothman, D. A. (1999). Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res 27, 2165-2174. Zellweger, T., Kiyama, S., Chi, K., Miyake, H., Adomat, H., Skov, K., and Gleave, M. E. (2003). Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. Bju Int 92, 463-469. Zhang, H. L., Kim, J. K., Edwards, C. A., Xu, Z. H., Taichman, R., and Wang, C. Y. (2005). Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 7, 909-U969. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62898 | - |
| dc.description.abstract | 在台灣,肝細胞癌屬於盛行率第三名的惡性腫瘤。因為肝細胞癌的轉移率和術後腫瘤的復發率都相當高,使得肝細胞癌的預後非常差。放射線治療是一種普遍用來治療癌症的策略,利用高能量的放射線達到殺死癌細胞的目的。隨著放射線和影像診斷技術的進步,醫生可以直接透過立體定位的方式精準地將高能量放射線傳遞到腫瘤的位置。但是對於肝細胞癌,放射線治療的效果沒有比目前的主要治療肝細胞癌的方法更加有效,加上肝細胞對於放射線的容忍度低,且肝癌細胞和正常肝細胞的放射線敏感度差異性不高,使得放射性治療沒有歸納在肝細胞癌的正規治療方針中。為了改善放射線治療在肝細胞癌治療上的侷限性,以及找到有潛力的藥物標靶加強放射性治療對於肝細胞癌的療效,我們利用人類肝細胞癌細胞株Huh7及全基因組核醣核酸干擾篩選技術來鑑定人類肝細胞癌的放射線保護基因和放射線敏感基因(放射線保護基因: 當基因表現受到抑制時,可使細胞增加對放射線的敏感度; 放射線敏感基因: 基因表現受到抑制時,使細胞對放射線的抵抗性增加)。我們從實驗結果篩選到二十一個候選基因,包括了十六個放射線保護基因和五個放射線敏感基因。這些候選基因利用細胞群落形成分析的驗證後得到十四個放射線保護基因,當中又以Clusterin (CLU) 基因影響放射線敏感度的效果最為顯著。透過流式細胞儀分析細胞在經過放射線處理後細胞死亡的情形,除了更加確認CLU影響細胞放射線敏感度的角色,也發現此現象只專一地在游離放射線處理後出現。而在紫外線處理下CLU基因的抑制沒有明顯地促進細胞死亡,然而其詳細的功能與機制仍須日後進一步的探討。 | zh_TW |
| dc.description.abstract | Hepatocellular carcinoma (HCC), the third most prevalent malignant tumor in Taiwan, has a poor prognosis due to high rates of recurrence and metastasis. Radiotherapy is one of the modalities in cancer treatments. With the recent development of stereotactic radiosurgery technology, physicians can deliver precise doses of energy to an exact location (i.e. the tumor) and thus limit collateral damage to surrounding normal tissues. Despite such an advanced technology, radiotherapy has not yet been incorporated into standard management guidelines of HCC because of the unsatisfactory clinical outcomes. In order to improve the efficacy of radiotherapy in treating HCC, we carried out a genome-wide RNA-interference (RNAi) screen in Huh7 cells (a human HCC cell line) and identified many genes as radiation protector candidates (i.e. knockdown of such genes increases the sensitivity of Huh7 cells to a predetermined dose of radiation) which might be used as potential targets for drug design to enhance radiation sensitivity of HCC. We identified twenty-one candidates from the screening results, including sixteen radioprotectors and five radiosensitizers. All of the candidates were validated by colony formation assay. Among these candidates, clusterin is the most significant radio-protector. Here we demonstrated that suppression of clusterin expression enhances the radiation-mediated cell death. Furthermore, the phenomenon caused by clusterin suppression is specific for ionizing radiation, but not for ultraviolet (UV) radiation. However, the detailed mechanisms and functions of clusterin need to be further studied and elucidated in the future. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T16:14:09Z (GMT). No. of bitstreams: 1 ntu-102-R99442024-1.pdf: 23270964 bytes, checksum: 2c1a886390dc5007a1ac1a7be7113f17 (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | 口試委員審定書 1
Acknowledgement 2 摘要 3 Abstract 4 Contents 5 Figure Contents 7 Table Contents 8 Chapter 1 Introduction 9 1.1 Hepatocellular Carcinoma 9 1.2 Radiotherapy for Hepatocellular Carcinoma 10 1.3 RNA interference (RNAi) screen 10 1.4 Clusterin 12 Chapter 2 Materials and Methods 14 2.1 Cell culture 14 2.2 shRNA lentivirus particle production and transduction 14 2.3 Large-scale transduction for RNAi screen 14 2.4 shRNA half-hairpin probe production 15 2.5 Microarray hybridization and analysis 16 2.6 Total RNA extraction and quantitative realtime polymerase chain reaction (qRT-PCR) 16 2.7 DNA histogram analysis by flow cytometer 17 2.8 Cell apoptosis analysis by flow cytometer 17 2.9 Colony formation assay 18 2.10 Western blot analysis 18 2.11 Plasmid end joining assay 18 2.12 Mouse xenograft model 19 Chapter 3 Results 20 Chapter 4 Discussion and Conclusion 24 Chapter 5 Figures 27 Chapter6 Tables 44 References 48 | |
| dc.language.iso | en | |
| dc.subject | 肝細胞癌 | zh_TW |
| dc.subject | 放射線治療 | zh_TW |
| dc.subject | 全基因組核醣核酸干擾篩選技術 | zh_TW |
| dc.subject | 放射線保護基因 | zh_TW |
| dc.subject | Radiotherapy | en |
| dc.subject | Hepatocellular carcinoma | en |
| dc.subject | Radioprotector | en |
| dc.subject | Genome-wide RNA interference screen | en |
| dc.title | 利用全基因組核醣核酸干擾篩選技術鑑定人類肝細胞癌的放射線保護基因 | zh_TW |
| dc.title | Identification of Radioprotectors in Human Hepatocellular Carcinoma by Genome-Wide RNAi Screening | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 101-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 顏伯勳,陳美齡,鄧述諄 | |
| dc.subject.keyword | 肝細胞癌,放射線治療,全基因組核醣核酸干擾篩選技術,放射線保護基因, | zh_TW |
| dc.subject.keyword | Hepatocellular carcinoma,Radiotherapy,Genome-wide RNA interference screen,Radioprotector, | en |
| dc.relation.page | 49 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2013-02-07 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
| 顯示於系所單位: | 生物化學暨分子生物學科研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 22.73 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
